5.1 How can case-finding for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of hepatitis B and hepatitis C infection are identified and tested?
5.2 How can the uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and complete hepatitis C treatment?
5.3 What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and secondary care?
5.5 How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C?
5.6 What are the most effective ways of involving people from groups at increased risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective are peer mentor programmes at increasing the number of people at increased risk who are tested and treated for hepatitis B and C?
5.7 What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment?
5.8 Which interventions for other communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment?
5.9 How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?
5.10 How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?
5.11 How cost effective are cohort testing programmes:
as a stand-alone programme, or
as an extension of the NHS Health Check programme?
More detail on the gaps in the evidence identified during development of this guidance is provided in appendix D.